Maintenance of peripheral and central intravenous infusion devices by 0.9% sodium chloride with or without heparin as a potential source of catheter microbial contamination

2000 ◽  
Vol 46 (2) ◽  
pp. 161-162 ◽  
J. Calop ◽  
J.L. Bosson ◽  
J. Croizé ◽  
P.E. Laurent
1909 ◽  
Vol 11 (5) ◽  
pp. 627-640
Moyer S. Fleisher ◽  
Leo Loeb

1. As a result of the intravenous infusion of a solution of sodium chloride a characteristic curve indicating the fluid retained in the vascular system is obtained. In the first period of the infusion the maximum of retention of fluid is noted. Then more fluid is removed from the blood vessels, so that for a short time a fall in the curve of dilution takes place, after which the dilution again slowly increases. 2. This curve is not materially changed by the addition of calcium chloride or of adrenalin to the infused solution, and under such conditions adrenalin does not lead to an increased pressing out of fluid from the vascular system, although is causes a constant and decided rise in blood pressure. Myocarditic lesions lead to an increased intravascular retention of fluid. Nephrectomy does not lead to an increased intravascular retention of fluid, but probably causes a diminution of the amount of fluid retained in the blood vessels.

1967 ◽  
Vol 45 (6) ◽  
pp. 925-936 ◽  
André Lanthier ◽  
Thomas Sandor

The osmotic regulation of the salt gland secretion was studied in the domestic duck. The response to the intravenous infusion of 5% sodium chloride (850 meq Na per liter) was established in unanesthetized ducks. Sodium bicarbonate (892 meq Na/l) produced a salt gland secretion similar to that after 5% sodium chloride, except that it was accompanied by a moderate diuresis. Mannitol and sucrose had similar effects. On the other hand, urea, ammonium chloride, dextran, and meralluride produced only a small amount of salt-gland secretion of low electrolyte concentration. Antidiuretic doses of Pitressin did not induce secretion of the salt gland.

2005 ◽  
Vol 18 (4) ◽  
pp. 791-798 ◽  
R. Anacardio ◽  
S. Bartolini ◽  
M.M. Gentile ◽  
M. Bagnasco ◽  
G. Carlucci

Ketoprofen lysine salt (Artrosilene®, injectable solution) is a non-steroidal anti-inflammatory agent frequently administered by slow intravenous infusion with portable elastomeric infusion systems in association regimen with other analgesic drugs. The aim of this study was to investigate the physicochemical compatibility between ketoprofen lysine salt (Artrosilene®, injectable solution) and other injectable drugs frequently used in association, such as tramadol hydrochloride, keterolac tromethamine and morphine hydrochloride, into the Infusor LV5, Baxter elastomeric infusion system. Physicochemical properties of drug mixture, including colour, clarity, pH and drug content were observed or measured by a reversed-phase HPLC method with UV detection, before and after (up to 7 days) mixing at room temperature and under light protection. The results obtained demonstrated the physicochemical compatibility of ketoprofen lysine salt (Artrosilene®, injectable solution) with all drug formulations at every tested mixing ratios into Baxer Infusor LV5 infusion devices.

1998 ◽  
Vol 26 (1) ◽  
pp. 51-55 ◽  
W. M. Widdowson ◽  
L. Walker ◽  
J. H. Havill ◽  
J. W. Sleigh

Arterial lines with three-way taps are used to measure blood pressure and aspirate blood, and are a potential source of catheter-related sepsis. Swabs were taken daily from 118 three-way taps on 98 arterial lines in a general intensive care unit. Infusion lines were changed weekly but arterial cannulae were not changed routinely. An overall contamination rate of 24.6% was found with the predominant organism being coagulase negative staphylococcus. The three-way taps became increasingly contaminated with time but this was shown to be unrelated to the manipulation rates. Blood culture organisms in those showing contamination of the three-way taps showed no relationship to the bacteria causing the contamination.

2017 ◽  
Vol 25 (2) ◽  
pp. 269-278 ◽  
William C Lamanna ◽  
Katharina Heller ◽  
Daniel Schneider ◽  
Raffaele Guerrasio ◽  
Veronika Hampl ◽  

Purpose The purpose of this study was to evaluate the in-use physicochemical and biological stability of the Sandoz rituximab biosimilar, marketed under the trade names Rixathon® and Riximyo® in the European Union, upon preparation for intravenous infusion. Methods Three batches of Rixathon®/Riximyo® in the final month of their 36 month shelf life were exposed to room temperature and light for 14 days to recapitulate a major temperature excursion. Samples were diluted to the lowest allowable concentration of 1 mg/mL in 0.9% NaCl solution in either polypropylene or polyethylene infusion bags and stored for 14 or 30 days at 5 ± 3℃ followed by an additional 24 h at room temperature to simulate product handling. Samples stored in infusion bags were analyzed using SEC, CEX, non-reducing CE-SDS, peptide mapping and CDC to assess physicochemical and biological stability. Results Analysis of Rixathon®/Riximyo® diluted to the lowest allowable concentration in 0.9% sodium chloride in either polypropylene or polyethylene infusion bags revealed no change in molecular weight variants, charge variants, deamidation, oxidation, overall composition or potency over a 31-day period. Conclusion Physicochemical and biological analyses demonstrate that Rixathon®/Riximyo® stability is not impacted by dilution and formulation conditions required for intravenous infusion, even under worst case conditions with regard to product shelf life, temperature excursion, light exposure, dilution factor and infusion bag storage time over a 31-day period.

2016 ◽  
Vol 94 (7) ◽  
pp. 533-539
Irina V. Gatckikh ◽  
M. M. Petrova ◽  
T. P. Shalda ◽  
E. L. Varygina ◽  
M. N. Kuznetsov ◽  

The aim of thisstudy was to investigatethe efficiency ofmetabolic therapyincorrectionof cognitive impairmentin patientswith type 2 diabetes. We undertook the analysis of results of the treatment of cognitive dysfunction in 80 patients with a diagnosis of type 2 diabetes. All patients received basic hypoglycemic therapy. 32 patients (study group) received in addition to the basal glucose lowering therapy daily intravenous infusion of 10 mlcytoflavindiluted in 200 ml of a 0.9% sodium chloride solution for 10 days, followed by 2 tablets b.i.d. for 25 days.The group of comparison consisted of 29 patients given in addition to the basal glucose-lowering therapy daily intravenous infusion of 24 ml (600 mg) thioctacid diluted in 200 mL of a 0.9% sodium chloride solution for 10 days. Thereafter, they received 1 tablet ofthioctacid BV once dailyfor 30 days. The control group consisted of 19 patients who received basic hypoglycemic therapy without additional metabolic therapy.Inclusion of cytoflavin in the combined treatment ofpatients with type 2 diabetes ensured a more effective correction of cognitive impairment. There was a statistically significant improvement in optical-spatial activities (p = 0.001), attention (p = 0.001), abstract thinking (p = 0.046), and memory (p<0.001) compared to those in other groups, according to the MOS test. Positive dynamics was expressed as the improvement of the optical-spatial activities by 9,8 ± 10,3%, attention by 13,5 ± 11,8%, abstract thinking by 7,0 ± 8,9%, and memory by 23.0 ± 14 6%. The study of variations of the serum level of brain neurotrophic factor (BDNF) over time during the treatment with metabolic preparations revealedits statistically significant increase (p = 0.002) in the patients treated with cytoflavincompared with comparison (p = 0.139) and control (p = 0.078) groups. These results suggest the influence of cytoflavinon the processes of neuroplasticity under conditions of hyperglycemia, improvement of cerebral microcirculation and cerebroprotective action of this medication.

Sign in / Sign up

Export Citation Format

Share Document